

## AGE Reader Key Publications

---

- **Lifestyle and clinical determinants of skin autofluorescence in a population-based cohort study.**  
van Waateringe R. et al. Eur J Clin Invest. 2016 Mar 22. Epub.
- **Skin autofluorescence provides additional information to the UK Prospective Diabetes Study (UKPDS) risk score for the estimation of cardiovascular prognosis in type 2 diabetes mellitus.**  
Lutgers H. et al, Diabetologia, 2009; 52(5): 789-797
- **Skin autofluorescence and risk of micro- and macrovascular complications in patients with Type 2 diabetes mellitus-a multi-centre study.**  
Noordzij M.J. et al. Diabet Med. 2012 Dec;29(12):1556-61.
- **Skin Autofluorescence and the Association with Renal and Cardiovascular Risk Factors in Chronic Kidney Disease Stage 3.**  
McIntyre N. et al. Clin J Am Soc Nephrol. 2011 Sep 1. Epub
- **Skin Autofluorescence: A tool to identify type 2 diabetic patients at risk for developing microvascular disease.**  
Gerrits E. et al. Diabetes Care. 2008; 31: 517-521
- **Messung der Autofluoreszenz der Haut.**  
Stirban A. and Heinemann L. Diabetes Stoffw Herz. 2013; 22 (full text available)
- **Skin Autofluorescence Is Associated With 5-Year Mortality and Cardiovascular Events in Patients With Peripheral Artery Disease.**  
de Vos LC. et al. Arterioscler Thromb Vasc Biol. 2014 Feb 13.
- **Simple non-invasive assessment of advanced glycation endproducts accumulation.**  
Meerwaldt R et al, Diabetologia, 2004; 47:1324-1330

## AGE Reader in diabetes

---

1. **Skin autofluorescence is increased in young people with type 1 diabetes exposed to secondhand smoking.**  
Vollenbrock CE. et al. J Diabetes. 2016 Oct 27. (Epub).
2. **Higher skin autofluorescence in young people with Type 1 diabetes and microvascular complications.**  
Cho YH. et al. Diabet Med. 2016 Oct 22. (Epub)
3. **Advanced glycation end products is a risk for muscle weakness in Japanese patients with type 1 diabetes.**  
Mori H. et al. J Diabetes Investig. 2016 Oct 11. (Epub) (FULL TEXT available)
4. **Skin Autofluorescence is Associated with Early-stage Atherosclerosis in Patients with Type 1 Diabetes.**  
Osawa S et al. J Atheroscler Thromb. 2016 Sep 2.
5. **Skin autofluorescence predicts cardio-renal outcome in type 1 diabetes: a longitudinal study.**  
Vélayoudom-Céphise FL et al. Cardiovasc Diabetol. 2016 Sep 1;15(1):127.
6. **Skin Autofluorescence and Pentosidine Are Associated With Aortic Stiffening: The Maastricht Study.**  
van Eupen MG et al. Hypertension. 2016 Oct;68(4):956-63.
7. **Skin fluorescence as a clinical tool for non-invasive assessment of advanced glycation and long-term complications of diabetes.**  
Fokkens BT, Smit AJ. Glycoconj J. 2016 Aug;33(4):527-35.

- 8. ADVANCED GLYCATION END PRODUCT (AGE) ACCUMULATION IN THE SKIN IS ASSOCIATED WITH DEPRESSION: THE MAASTRICHT STUDY.**  
van Dooren FE et al. *Depress Anxiety*. 2016 Jun 6. (Epub)
- 9. Skin autofluorescence and peripheral neuropathy four years later in type 1 diabetes.**  
Rajaobelina K. et al. *Diabetes Metab Res Rev*. 2016 May 27. Epub
- 10. The relationship between advanced glycation endproducts and ocular circulation in type 2 diabetes.**  
Hashimoto K. et al. *J Diabetes Complications* 2016 May 4. Epub.
- 11. Advanced Glycation Endproducts and Bone Material Strength in Type 2 Diabetes.**  
Furst J.R. et al. *J Clin Endocrinol Metab*. 2016 Apr 26. Epub.
- 12. Association of Advanced Glycation End Products with coronary Artery Calcification in Japanese Subjects with Type 2 Diabetes as Assessed by Skin Autofluorescence.**  
Hangai M. et al. *J Atheroscler Thromb*. 2016 Mar 10.
- 13. Non-invasive Measurement of Skin Autofluorescence as a Beneficial Surrogate Marker for Atherosclerosis in Patients with Type 2 Diabetes.**  
Temma J. et al. *J Med Invest*. 2015;62(3-4):126-9.
- 14. Advanced glycation end products, measured in skin, vs. HbA1c in children with type 1 diabetes mellitus.**  
Banser A. et al. *Pediatr Diabetes*. 2015 Sep 2.
- 15. Relationship between skin auto fluorescence and conventional glycemic markers in patients with diabetes.**  
Mácsai E. et al. *Orv Hetil*. 2015 Aug 16;156(33):1341-7.
- 16. In diabetic Charcot neuroarthropathy impaired microvascular function is related to long lasting metabolic control and low grade inflammatory process.**  
Araszkievicz A. et al. *Microvasc Res*. 2015 Aug 1;101:143-147.
- 17. Vitamin D status is associated with skin autofluorescence in patients with type 2 diabetes mellitus: a preliminary report.**  
Krul-Poel Y.H. et al. *Cardiovasc Diabetol*. 2015 Jul 16;14:89.
- 18. Is skin autofluorescence a marker of metabolic memory in pregnant women with diabetes?**  
Maury E. et al. *Diabet Med*. 2015 May 16.
- 19. The Association Between Skin Autofluorescence and Vascular Complications in Chinese Patients With Diabetic Foot Ulcer: An Observational Study Done in Shanghai.**  
Liu C. et al. *Int J Low Extrem Wounds*. 2015. (Epub)
- 20. Autofluorescence of Skin Advanced Glycation End Products: Marker of Metabolic Memory in Elderly Population.**  
Rajaobelina K. et al. *J Gerontol A Biol Sci Med Sci*. 2015 Jan 14 (Epub)
- 21. Skin autofluorescence is associated with carotid intima-media thickness, diabetic microangiopathy, and long-lasting metabolic control in type 1 diabetic patients. Results from Poznan Prospective Study.**  
Araszkievicz A. et al. *Microvasc Res*. 2015 Jan 10 (Epub)
- 22. Association of advanced glycation end products and chronic kidney disease with macroangiopathy in type 2 diabetes.**  
Rigalleau V. et al. *J Diabetes Complications*. 2014 Oct 30. Epub
- 23. Advanced glycation end products (AGEs) and the soluble receptor for AGE (sRAGE) in patients with type 1 diabetes and coeliac disease.**  
Bakker S.F. et al. *Nutr Metab Cardiovasc Dis*. 2014 Nov 1.Epub
- 24. Associations of advanced glycation endproducts with cognitive functions in individuals with and without type 2 diabetes.**  
Spauwen P.J. et al. *J Clin Endocrinol Metab*. 2014 Dec 2
- 25. Relationship of Skin Autofluorescence to Severity of Retinopathy in Type 2 Diabetes.**  
Yasuda M. et al. *Curr Eye Res*. 2014 May 28:1-8.
- 26. Type 2 diabetes mellitus, skin autofluorescence and brain atrophy.**  
Moran C. et al. *Diabetes*. 2014 Jul 22.

- 27. AGEs and chronic subclinical inflammation in diabetes: disorders of immune system.**  
Hu H. et al. Diabetes Metab Res Rev. 2014 May 20. Epub
- 28. Correlation between diabetic makuls severity and elevated skin autofluorescence as a marker of advanced glycation end-product accumulation in type 2 diabetic patients.**  
Hirano T. et al. J Diabetes Complications. 2014 Mar 10. Epub
- 29. Advanced glycation end products are associated with arterial stiffness in type 1 diabetes.**  
Llauradó G. et al. J Endocrinol. 2014 Jun;221(3):405-13.
- 30. Messung der Autofluoreszenz der Haut.**  
Stirban A. and Heinemann L. Diabetes Stoffw Herz. 2013; 22 (full text available)
- 31. Skin autofluorescence relates to soluble receptor for advanced glycation end-products and albuminuria in diabetes mellitus.**  
Skrha J Jr. et al. J Diabetes Res. Epub 2013 Mar 10.
- 32. Skin autofluorescence based decision tree in detection of impaired glucose tolerance and diabetes.**  
Smit AJ. et al. PLoS One. 2013 Jun 4;8(6):e65592.
- 33. Potential inhibitory effects of L-carnitine supplementation on tissue advanced glycation end products in patients with hemodialysis.**  
Fukami K. Rejuvenation Res. 2013 Aug 4. [Epub ahead of print]
- 34. Skin autofluorescence relates to soluble receptor for advanced glycation end-products and albuminuria in diabetes mellitus.**  
Skrha J Jr. et al. J Diabetes Res. 2013;2013:650694.
- 35. Skin autofluorescence is associated with past glycaemic control and complications in type 1 diabetes mellitus.**  
Genevieve M. et al. Diabetes Metab. 2013 May 2. [Epub ahead of print]
- 36. Advanced Glycation End Products Assessed by Skin Autofluorescence-A New Marker of Diabetic Foot Ulceration.**  
Vouillarmet J. et al. Diabetes Technol Ther. 2013 Apr 30. [Epub ahead of print]
- 37. Study design of DIACORE (DIAbetes COHoRtE) - a cohort study of patients with diabetes mellitus type 2.**  
Dörhöfer L, BMC Med Genet. 2013 Feb 14;14:25.
- 38. Verification of Skin Autofluorescence Values by Mass Spectrometry in Adolescents with Type 1 Diabetes: Brief Report.**  
Mácsai E. et al. Diabetes Technol Ther. 2013 Jan 23.
- 39. Advanced glycation end products in infant formulas do not contribute to insulin resistance associated with their consumption.**  
Klenovics KS. et al. PLoS One. 2013;8(1):e53056.
- 40. Advanced Glycation End Products, Measured as Skin Autofluorescence, During Normal Pregnancy and Pregnancy Complicated by Diabetes Mellitus.**  
de Ranitz-Greven WL. et al. Diabetes Technol Ther. 2012 Oct 31. (Epub)
- 41. Skin autofluorescence measurement in diabetological and nephrological clinical practice.**  
Mácsai E. et al. Orv Hetil. 2012 Oct 21;153(42):1651-7.
- 42. Skin autofluorescence and risk of micro- and macrovascular complications in patients with Type 2 diabetes mellitus-a multi-centre study.**  
Noordzij M.J. et al. Diabet Med. 2012 Aug 31. doi: 10.1111/dme.12005.
- 43. Advanced glycation end products measured by skin autofluorescence in a population with central obesity.**  
den Engelsen C. et al. Dermatoendocrinol. 2012 Jan 1;4(1):33-8.
- 44. Elevated skin autofluorescence is strongly associated with foot ulcers in patients with diabetes: a cross-sectional, observational study of Chinese subjects.**  
Hu H. et al. J Zhejiang Univ Sci B. 2012 May;13(5):372-7.
- 45. Advanced Glycation Endproducts and Diabetic Cardiovascular Disease.**  
Prasad A. et al. Cardiol Rev. 2012 Feb 6. Epub

46. **Non-invasive measures of tissue autofluorescence are increased in Type 1 diabetes complications and correlate with a non-invasive measure of vascular dysfunction.**  
Januszewski A.S. et al. Diabet Med. 2011 Dec 28. doi: 10.1111/j.1464-5491.2011.03562.x.
47. **Skin autofluorescence is associated with severity of vascular complications in Japanese patients with Type 2 diabetes.** Tanaka K. et al. Diabet Med. 2011 Sep 14. Epub
48. **Skin autofluorescence is inversely related to HDL anti-oxidative capacity in type 2 diabetes mellitus.**  
Mulder D. et al. Atherosclerosis. 2011 May, Epub
49. **Advanced Glycation End Products, Measured as Skin Autofluorescence, at Diagnosis in Gestational Diabetes Mellitus Compared with Normal Pregnancy.**  
de Ranitz-Greven WL et al. Diabetes Technol Ther. 2011 Aug 29. Epub
50. **Increased accumulation of skin advanced glycation end products is associated with microvascular complications in type 1 diabetes.**  
Araszkiewicz A. et al. Diabetes Technol Ther. 2011 Aug;13(8):837-42.
51. **Assessment of skin autofluorescence as a marker of advanced glycation end product accumulation in type 1 diabetes.**  
Samborski P. et al. Pol Arch Med Wewn. 2011 Mar;121(3):67-72.
52. **Advanced glycation end products, measured as skin autofluorescence and diabetes complications: a systematic review.**  
Bos D.C. et al. Diabetes Technol Ther. 2011 Jul;13(7):773-9.
53. **Tissue advanced glycation end products are associated with diastolic function and aerobic exercise capacity in diabetic heart failure patients.**  
Willemsen S. et al. Eur J. Heart Fail 2010. doi:10.1093/eurjhf/hfq168
54. **Skin autofluorescence and glycemic variability.**  
Noordzij M. et al. Diabetes Technol Ther. 2010; 12(7): 581-585
55. **Advanced glycation end products assessed by skin autofluorescence in type 1 diabetics are associated with nephropathy, but not retinopathy.**  
Chabroux S. et al: Diabetes Metab, 2010 Apr;36(2):152-7.
56. **Skin autofluorescence provides additional information to the UK Prospective Diabetes Study (UKPDS) risk score for the estimation of cardiovascular prognosis in type 2 diabetes mellitus**  
Lutgers H. et al: Diabetologia, 2009; 52(5): 789-797
57. **Skin Autofluorescence: A tool to identify type 2 diabetic patients at risk for developing microvascular disease.**  
Gerrits E. et al. Diabetes Care. 2008; 31: 517-521
58. **Skin autofluorescence is a strong predictor of cardiac mortality in diabetes**  
Meerwaldt R, et al. Diabetes Care 2007, 30: 107-112
59. **Skin autofluorescence in type 2 diabetes: Beyond blood glucose**  
Monami M. et al. Diabetes Research & Clinical Practice July 2007. epub
60. **Non-invasive AGE-measurements by skin autofluorescence in patients with Type 2 Diabetes Mellitus. Tool for risk-assessment of diabetes complications?**  
Lutgers H, et al. Diabetes Care. 2006 Dec;29(12):2654-9
61. **Increased accumulation of skin advanced glycation end-products precedes and correlates with clinical manifestation of diabetic neuropathy**  
Meerwaldt R, et al. Diabetologia. 2005;48:1637-44.
62. **The clinical relevance of advanced glycation endproducts (AGE) and recent developments in pharmaceuticals to reduce AGE accumulation.**  
Smit AJ, Lutgers HL.Curr Med Chem. 2004 Oct;11(20):2767-84.

## AGE Reader in cardiovascular disease

---

- 63. Association of Skin Autofluorescence Levels With Kidney Function Decline in Patients With Peripheral Artery Disease.**  
Schutte E et al. *Arterioscler Thromb Vasc Biol.* 2016 Aug;36(8):1709-14.
- 64. The Relationship Between Level of End-Products of Tissue Glycation and Pulse Wave Velocity in Non-diabetic Patients With Cardiovascular Disease.**  
Ageev F.T. et al. *Kardiologija.* 2015;55(6):63-7.
- 65. Skin autofluorescence as a measure of advanced glycation end products deposition predicts 5-year amputation in patients with peripheral artery disease.**  
de Vos LC. et al. *Arterioscler Thromb Vasc Biol.* 2015 Jun;35(6):1532-7.
- 66. Evaluation of tissue accumulation levels of advanced glycation end products by skin autofluorescence: A novel marker of vascular complications in high-risk patients for cardiovascular disease.**  
Yamagishi S.I. et al. *Int J Cardiol.* 2015 Mar (Epub)
- 67. Skin autofluorescence, 5-year mortality, and cardiovascular events in peripheral arterial disease: all that glitters is surely not gold.**  
Schmidt AM. *Arterioscler Thromb Vasc Biol.* 2014 Apr;34(4):697-9.
- 68. Skin Autofluorescence Is Associated With 5-Year Mortality and Cardiovascular Events in Patients With Peripheral Artery Disease.**  
de Vos LC. et al. *Arterioscler Thromb Vasc Biol.* 2014 Feb 13.
- 69. Skin Autofluorescence, a Non-Invasive Marker for AGE Accumulation, Is Associated with the Degree of Atherosclerosis.**  
den Dekker MA. et al. *PLoS One.* 2013 Dec 23;8(12):e83084.
- 70. Skin autofluorescence as proxy of tissue AGE accumulation is dissociated from SCORE cardiovascular risk score, and remains so after 3 years.**  
Tiessen AH. et al. *Clin Chem Lab Med.* 2013 Apr 2:1-7.
- 71. Skin Autofluorescence as a Measure of Advanced Glycation End Product Deposition Is Elevated in Peripheral Artery Disease.**  
de Vos L.C. et al. *Arterioscler Thromb Vasc Biol.* 2012 Nov 8. (Epub)
- 72. Relationship between tissue glycation measured by autofluorescence and pulse wave velocity in young and elderly non-diabetic populations.**  
Wafar G. et al. *Diabetes Metab.* 2012 Jun 13.
- 73. Advanced glycation end product associated skin autofluorescence: A mirror of vascular function?**  
Hofmann B. et al. *Exp Gerontol.* 2012 May 12.
- 74. Effects of alagebrium, an advanced glycation endproduct breaker, on exercise tolerance and cardiac function in patients with chronic heart failure.**  
Hartog J.W. et al. *BENEFICIAL investigators. Eur J Heart Fail.* 2011 Aug;13(8):899-908.
- 75. Skin autofluorescence is increased in patients with carotid artery stenosis and peripheral artery disease.**  
Noordzij MJ. *Int J Cardiovasc Imaging.* 2011 Feb. Epub
- 76. Carotid artery intima media thickness associates with skin autofluorescence in non-diabetic subjects without clinically manifest cardiovascular disease.**  
Lutgers H. et al. *Eur J Clin Invest.* 2010 ;40(9):812-7
- 77. Advanced glycation end-products, anti-hypertensive treatment and diastolic function in patients with hypertension and diastolic dysfunction.**  
Hartog J. et al; *Eur. Journal of Heart Failure,* 2010 Apr;12(4):397-403
- 78. Advanced glycation end products in patients with cerebral infarction.**  
Ohnuki Y. *Intern Med.* 2009;48(8):587-91.
- 79. Advanced Glycation End Products and their receptor RAGE in systemic autoimmune diseases - an inflammation propagating factor contributing to accelerated atherosclerosis.**  
Nienhuis et al. *Autoimmunity,* 2009; 42(4): 302-304

- 80. Skin autofluorescence is elevated in acute myocardial infarction and is associated with the one-year incidence of major adverse cardiac events**  
Mulder D. et al, Netherlands Heart Journal, Volume 17, Number 4, April 2009
- 81. Relation between food and drinking habits, and skin autofluorescence and intima media thickness in subjects at high cardiovascular risk**  
Jochemsen M. et al: Journal of Food and Nutrition Research Vol. 48, 2009, No. 1, pp. 51–58
- 82. Advanced Glycation Endproducts (AGE) in chronic heart failure**  
Smit A. et al. Annals of New York Academy of Science 2008; 1126:225-30
- 83. Clinical relevance of Advanced Glycation Endproducts for vascular surgery**  
Meerwaldt R. et al. Eur J Vasc Endovasc Surg. 2008; 38,125-131
- 84. Skin autofluorescence is elevated in patients with stable coronary artery disease and is associated with serum levels of neopterin and the soluble receptor for advanced glycation end products.**  
Mulder DJ. et al. Atherosclerosis. 2007;197:217-223
- 85. Clinical and prognostic value of Advanced Glycation End-products (AGEs) in chronic heart failure.**  
Hartog J. et al Eur J Heart Failure 2007;9:1146-55
- 86. Skin Autofluorescence is an independent marker for Acute Myocardial Infarction**  
Mulder DJ, et al. Circulation: 2005; 112:II-371.

## AGE Reader in renal disease

---

- 87. Comparing changes in plasma and skin autofluorescence in low-flux versus high-flux hemodialysis.**  
Ramsauer B. et al. Int J Artif Organs. 2015 (Epub)
- 88. Skin Autofluorescence Is Associated with Endothelial Dysfunction in Uremic Subjects on Hemodialysis.**  
Wang CC. et al. PLoS One. 2016 Jan 25;11(1):e0147771.
- 89. Skin autofluorescence advanced glycosylation end products (AGEs) as an independent predictor of mortality in high flux haemodialysis and haemodialysis patients.**  
Nongnuch A. et al. Nephrology (Carlton). 2015 May 25.
- 90. The effect of vegetarian diet on skin autofluorescence measurements in haemodialysis patients.**  
Nongnuch A. et al. Br J Nutr. 2015 Mar 12;114(4):1-4. (Epub)
- 91. Skin Autofluorescence Is a Predictor of Cardiovascular Disease in Chronic Kidney Disease Patients.**  
Furuya F. et al. Ther Apher Dial. 2014 Dec 29.
- 92. Tissue advanced glycation end products (AGEs), measured by skin autofluorescence, predict mortality in peritoneal dialysis.**  
Siriopol D. et al. Int Urol Nephrol. 2014 Nov 26.
- 93. Skin autofluorescence as a novel marker of vascular damage in children and adolescents with chronic kidney disease.**  
Makulska I. et al. Pediatr Nephrol. 2014 Nov 20.
- 94. Skin autofluorescence associates with vascular calcification in chronic kidney disease.**  
Maku A.Y. et al. Arterioscler Thromb Vasc Biol. 2014 Aug;34(8):1784-90
- 95. Skin Autofluorescence and All-Cause Mortality in Stage 3 CKD.**  
Fraser S.D. et al. Clin J Am Soc Nephrol. 2014 May 29. Epub
- 96. Skin Autofluorescence Predicts Cardiovascular Mortality in Patients on Chronic Hemodialysis.**  
Kimura H. et al. Ther Apher Dial. 2014 Jan 24
- 97. Skin autofluorescence is associated with the progression of chronic kidney disease: a prospective observational study.**  
Tanaka K. et al. PLoS One. 2013 Dec 12;8(12):e83799.

- 98. Skin and Plasma Autofluorescence During Hemodialysis: A Pilot Study.**  
Graaff R. et al. *Artif Organs*. 2013 Oct 29.
- 99. Tissue Advanced Glycation End Product Deposition after Kidney Transplantation.**  
Crowley LE et al. *Nephron Clin Pract*. 2013 Oct 15;124(1-2):54-59.
- 100. Advanced glycation end-products and skin autofluorescence in end-stage renal disease: a review.**  
Arsov S. et al. *Clin Chem Lab Med*. 2013 Apr 4:1-10.
- 101. Accumulation of tissue advanced glycation end products correlated with glucose exposure dose and associated with cardiovascular morbidity in patients on peritoneal dialysis.**  
Jiang J. et al. *Atherosclerosis*. 2012 Sep;224(1):187-94.
- 102. Skin autofluorescence as a marker of cardiovascular risk in children with chronic kidney disease.**  
Siriopol I. et al. *Pediatr Nephrol*. 2012 Sep 15. (Epub)
- 103. Factors influencing skin autofluorescence of patients with peritoneal dialysis.**  
Mácsai E. et al. *Acta Physiol Hung*. 2012 Jun;99(2):216-22.
- 104. Decreased serum carnitine is independently correlated with increased tissue accumulation levels of advanced glycation end products in hemodialysis patients.**  
Adachi T. et al. *Nephrology (Carlton)*. 2012 Jul 13. doi: 10.1111/j.1440-1797.2012.01642.x.
- 105. Skin Autofluorescence: A Pronounced Marker of Mortality in Hemodialysis Patients.**  
Gerrits E. et al. *Nephron Extra*. 2012 Jan;2(1):184-191.
- 106. Advanced oxidation protein products and advanced glycation end products in children and adolescents with chronic renal insufficiency.**  
Sebeková K. *J Ren Nutr*. 2012 Jan;22(1):143-8.
- 107. Evaluation of advanced glycation end products accumulation, using skin autofluorescence, in CKD and dialysis patients.** Oleniuc M. et al. *Int Urol Nephrol*. 2011 Oct;44(5):1441-9.
- 108. Skin autofluorescence and the association with renal and cardiovascular risk factors in chronic kidney disease stage 3.**  
McIntyre N.J. et al. *Clin J Am Soc Nephrol*. 2011 Oct;6(10):2356-63.
- 109. Tissue level of advanced glycation end products is an independent determinant of high-sensitivity C-reactive protein levels in haemodialysis patients.**  
Nagano M. et al. *Nephrology (Carlton)*. 2011 Mar;16(3):299-303
- 110. Skin autofluorescence as a measure of advanced glycation endproduct deposition: a novel risk marker in chronic kidney disease.**  
Smit AJ. et al. *Curr Opin Nephrol Hypertens*, 2010; 19(6):527-33.
- 111. Skin autofluorescence is associated with renal function and cardiovascular diseases in pre-dialysis chronic kidney disease patients.**  
Tanaka K. et al. *Nephrol Dial Transplant*. doi: 10.1093/ndt/gfq369
- 112. Advanced glycation end products, carotid atherosclerosis, and circulating endothelial progenitor cells in patients with end-stage renal disease.**  
Ueno H et al. *Metabolism*, 2010, doi: 10.1016/j.metabol.2010.04.001
- 113. Tissue-Advanced Glycation End Product Concentration in Dialysis Patients**  
McIntyre et al; *CJASN*, 2010; 5(1): 51-55
- 114. Does hepatitis C increase the accumulation of advanced glycation end products in haemodialysis patients?**  
Arsov S. et al. *Nephrol Dial Transplant* 2009; 25(3): 885-891
- 115. Skin-Autofluorescence Is an Independent Predictor of Graft Loss in Renal Transplant Recipients**  
Hartog J. et al, *Transplantation* • Volume 87, Number 7, April 15, 2009
- 116. Advanced Glycation End Products in Renal Failure: An Overview**  
Noordzij M. et al, *Journal of Renal Care* 2008
- 117. AGEs, autofluorescence and renal failure**  
Gerrits E. et al. *Nephrology Dialysis and Transplantation* November 25, 2008

- 118. Skin autofluorescence, a marker for advanced glycation end product accumulation, is associated with arterial stiffness in patients with end-stage renal disease**  
Ueno H. et al: Metabolism Clinical and Experimental 57 (2008) 1452–1457
- 119. Skin Autofluorescence, a measure of tissue advanced glycation endproducts (AGEs), is related to the diastolic function of dialysis patients**  
Hartog J. et al. Journal of Cardiac Failure. 2008; 14(7): 596-602
- 120. Risk factors for chronic transplant dysfunction and cardiovascular disease are related to accumulation of advanced glycation end-products in renal transplant recipients**  
Hartog JWL, et al. Nephrol Dial Transpl 2006 Aug;21(8):2263-9
- 121. Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation endproducts, predicts mortality in hemodialysis patients**  
Meerwaldt R, et al. J Am Soc Nephrol 2005;16:3687-93.
- 122. Skin autofluorescence, a noninvasive measure of advanced glycation end product accumulation, is a predictor of mortality in hemodialysis patients**  
Meerwaldt R, et al. Ann N Y Acad Sci 2005;1043:911.
- 123. Accumulation of advanced glycation end products, measured as skin autofluorescence, in renal disease.**  
Hartog JW. et al. Ann N Y Acad Sci. 2005 Jun;1043:299-307.
- 124. Advanced glycation endproducts in kidney transplant patients: a putative role in the development of chronic renal transplant dysfunction**  
Hartog J. et al. Am J Kidn Dis 2004; 43:966-975

## **AGE Reader in other diseases**

---

- 125. Skin advanced glycation end products in HIV infection are increased and predictive of development of cardiovascular events.**  
Sprenger HG. et al. AIDS. 2016 Oct 18.
- 126. The Course of Skin and Serum Biomarkers of Advanced Glycation Endproducts and Its Association with Oxidative Stress, Inflammation, Disease Severity, and Mortality during ICU Admission in Critically Ill Patients: Results from a Prospective Pilot Study.**  
Meertens JH et al. PLoS One. 2016 Aug 16;11(8). (FULL TEXT available)
- 127. Relationship between advanced glycation end-product accumulation and low skeletal muscle mass in Japanese men and women.**  
Kato M. et al. Geriatr Gerontol Int. 2016 Apr 27. Epub.
- 128. Advanced glycation endproducts and their receptor in different body compartments in COPD.**  
Hoonhorst S.J. et al. Respir Res. 2016 Apr 26; 17:46.
- 129. The association between systemic oxidative stress and ocular blood flow in patients with normal-tension glaucoma.**  
Himori N. et al. Graefes Arch Clin Exp Ophthalmol. 2016 Feb;254(2):333-41.
- 130. Skin Autofluorescence in Systemic Sclerosis Is Related to the Disease and Vascular Damage: A Cross-Sectional Analytic Study of Comparative Groups.**  
Dadoniene J. et al. Dis Markers. 2015;2015:837470. Epub
- 131. Traditional and emerging indicators of cardiovascular risk in chronic obstructive pulmonary disease.**  
John M. et al. Chron Respir Dis. 2016 Mar 10.
- 132. A new gender-specific model for skin autofluorescence risk stratification.**  
Ahmad M.S. et al. Sci Rep. 2015 May 14;5:10198.



- 133. Achilles tendons in people with type 2 diabetes show mildly compromised structure: an ultrasound tissue characterisation study.**  
de Jonge S. et al. Br J Sports Med. 2015 Jan 13 (Epub)
- 134. Does reduction of disease activity improve early markers of cardiovascular disease in newly diagnosed rheumatoid arthritis patients?**  
de Groot L. et al. Rheumatology (Oxford). 2015 Jan 12 (Epub)
- 135. Advanced glycation end products in the skin are enhanced in COPD.**  
Hoonhorst S.J. et al. Metabolism. 2014 Jun 13. Epub
- 136. Life-long endurance running is associated with reduced glycation and mechanical stress in connective tissue.**  
Couppe C. et al. Age (Dordr). 2014 Aug;36(4):9665.
- 137. Plasma AGEs and skin autofluorescence are increased in COPD.**  
Gopal P. et al. Eur Respir J. 2013 May 3. [Epub ahead of print]
- 138. Increased advanced glycation end-products (AGEs) assessed by skin autofluorescence in schizophrenia.**  
Kouidrat Y. et al. J Psychiatr Res. 2013 Apr 21.
- 139. Local differences in skin autofluorescence may not reflect similar differences in oxidative stress exposure.**  
Hetteema M. et al. J Rheumatol. 2013 Feb;40(2):206.
- 140. Vascular Aspects of Fabry Disease in Relation to Clinical Manifestations and Elevations in Plasma Globotriaosylsphingosine.**  
Rombach S.M. et al. Hypertension. 2012 Aug 6. (Epub)
- 141. Advanced Glycation Endproducts are increased in RA patients with controlled disease.**  
de Groot L. et al. Arthritis Res Ther. 2011 Dec 14;13(6):R205.
- 142. Increased skin autofluorescence after colorectal operation reflects surgical stress and postoperative outcome.**  
Pol H.W. et al. Am J Surg. 2011 Nov;202(5):583-9.
- 143. Skin autofluorescence, as marker of accumulation of advanced glycation endproducts and of cumulative metabolic stress, is not increased in patients with systemic sclerosis.**  
Hetteema M.E. et al. Int J Rheumatol. 2011. Epub
- 144. Skin advanced glycation end-product accumulation is negatively associated with calcaneal osteo-sono assessment index among non-diabetic adult Japanese men.**  
Momma H. Osteoporos Int. 2011 Sep 8. Epub
- 145. Skin autofluorescence is high in patients with cirrhosis - further arguing for the implication of Advanced Glycation End products.**  
Maury E. et al. J Hepatol. 2011 May;54(5):1079-80.
- 146. Skin advanced glycation end product accumulation and muscle strength among adult men.**  
Momma H. et al; Eur J Appl Physiol. 2010 (Epub)
- 147. Skin Autofluorescence as Marker of Tissue Advanced Glycation End-Products Accumulation in Formerly Preeclamptic Women.**  
Coffeng S.M. et al. Hypertens Pregnancy; 2010, Epub
- 148. Accumulation of advanced glycation end (AGEs) products in intensive care patients: an observational, prospective study.**  
Greven W. et al. BMC Clinical Pathology; 2010: 10 (4)
- 149. Increased accumulation of advanced glycation endproducts in patients with Wegener's granulomatosis.**  
Leeuw de K et al. Ann Rheum Dis. 2009; 69(3): 625-U191
- 150. Skin autofluorescence is increased in systemic lupus erythematosus but not reflected by plasma levels advanced glycation endproducts**  
Nienhuis H. et al; Rheumatology. 2008; 47(10): 1554-1558

- 151. Skin autofluorescence is increased in systemic lupus erythematosus but not reflected by plasma levels of advanced glycation endproducts**  
Nienhuis H. et al. Rheumatology; 2008; 47(10): 1554-1558
- 152. Advanced glycation end products and the absence of premature atherosclerosis in glycogen storage disease Ia**  
den Hollander NC. et al. J Inherit Metab Dis. 2007. epub ahead of print
- 153. Accumulation of advanced glycation endproducts in patients with systemic lupus erythematosus.**  
de Leeuw K. et al. Rheumatol 2007;45:1551-1556.
- 154. Skin autofluorescence, a marker of advanced glycation end products and oxidative stress, is increased in recently prelamptic women**  
Blaauw J. et al. Am J Obstet Gynecol. 2006 Sep;195(3):717-22.
- 155. Enhanced skin autofluorescence as a marker for oxidative stress in sepsis, a pilot study.**  
Mulder DJ, et al. Eur Soc Intensive Care Medicine 2004

## **AGE Reader (technical) validation**

---

- 156. Lifestyle and clinical determinants of skin autofluorescence in a population-based cohort study.**  
van Waateringe R. et al. Eur J Clin Invest. 2016 Mar 22. Epub.
- 157. Body mass index, chronological age and hormonal status are better predictors of biological skin age than arm skin autofluorescence in healthy women who have never smoked.**  
Randag A.C. et al. Br J Dermatol. 2015 Jul 25.
- 158. The skin autofluorescence reflects the posttranslational glycation grade of the matrix protein collagen.**  
Jacobs K. et al. Free Radic Biol Med. 2014 Oct;75 Suppl 1:S34
- 159. GWAS identifies an NAT2 acetylator status tag single nucleotide polymorphism to be a major locus for skin fluorescence.**  
Eny K.M. et al. Diabetologia. 2014 Aug;57(8):1623-34.
- 160. Reference values of skin autofluorescence as an estimation of tissue accumulation of advanced glycation end products in a general Slovak population.**  
Klenovics KS, Diabet Med. 2013 Sep 30. doi: 10.1111/dme.12326. (Epub).
- 161. Reference values for the Chinese population of skin autofluorescence as a marker of advanced glycation end products accumulated in tissue.**  
Yue X. et al. Diabet Med. 2011 Jul;28(7):818-23.
- 162. Dermal factors influencing measurement of skin autofluorescence.**  
Noordzij M.J. et al. Diabetes Technol Ther. 2011 Feb;13(2):165-70
- 163. Skin color independent assessment of aging using skin autofluorescence**  
Koetsier M. et al. Optics Express, 2010 ;18(14):14416-29
- 164. Reference Values of Skin Autofluorescence.**  
Koetsier M. et al. Diabetes Technology & Therapeutics 2010; 12(5):399-403
- 165. Skin autofluorescence for the risk assessment of chronic complications in diabetes: a broad excitation range is sufficient**  
Koetsier M. et al: Optics Express. 2009; 17(2): 509-519
- 166. Skin autofluorescence increases postprandially in human subjects**  
Stirban A. et al. Diabetes Technology & Therapeutics 2008: 10:200-5
- 167. The Effect of Aggressive Versus Conventional Lipid-lowering Therapy on Markers of Inflammatory and Oxidative Stress.**  
Mulder DJ. et al. Cardiovasc Drugs Ther. 2007 Apr;21(2):91-7.

**168. Skin Autofluorescence, a Novel Marker for Glycation and Oxidative Stress derived Advanced Glycation Endproducts. An Overview of Current Clinical Studies, Evidence and Limitations**

Mulder DJ, et al. Diabetes Technology and Therapeutics 2006; 8:523-535.

**169. Simple noninvasive measurement of skin autofluorescence**

Meerwaldt R, et al. Ann N Y Acad Sci. 2005;1043:290-298.

**170. Instrumentation for the measurement of Autofluorescence in the human skin**

Graaff R et al. Proc. of SPIE Vol. 5692 (SPIE, Bellingham, WA, 2005). pp. 111-118.

**171. Simple non-invasive assessment of advanced glycation endproducts accumulation**

Meerwaldt R et al. Diabetologia 2004; 47:1324-1330

---

**For more information please visit:**

[www.diagnoptics.com](http://www.diagnoptics.com)

[www.age-reader.com](http://www.age-reader.com)



DiagnOptics Technologies B.V. – Aarhusweg 4-9, 9723 JJ, Groningen, The Netherlands - [info@diagnoptics.com](mailto:info@diagnoptics.com)